Sergio Palomo-Ponce

Sergio Palomo-Ponce

Auto-generated profile, based on publicly available information

Sergio Palomo-Ponce

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
DSDiana Stork
Diana Stork
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
JBJordi Badia-Ramentol
Jordi Badia-Ramentol
EBEduard Batlle
Eduard Batlle
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers1,2. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration3, low type 1 T-helper cell (TH1) activity and reduced immune cytotoxicity2 or increased TGFβ levels4 predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden5, T-cell exclusion3 and TGFβ-activated stroma4,6,7. Inhibition of the PD-1–PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1–PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the TH1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.

1 November 2012 in Cancer Cell
Verified
Journal Article
Closed access
ACAlexandre Calon
Alexandre Calon
EEElisa Espinet
Elisa Espinet
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
MIMar Iglesias
Mar Iglesias
EBEduard Batlle
Eduard Batlle

23 February 2015 in Nature Genetics
Verified
Journal Article
Closed access
ACAlexandre Calon
Alexandre Calon
ELEnza Lonardo
Enza Lonardo
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
EEElisa Espinet
Elisa Espinet
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle

30 December 2003 in Genes & Development
Verified
Journal Article
Open access
PDF file
LTLuika A. Timmerman
Luika A. Timmerman
JGJoaquín Grego-Bessa
Joaquín Grego-Bessa
Angel RayaAngel Raya
Angel Raya
EBEsther Bertran
Esther Bertran
JPJose M. Perez-Pomares
Jose M. Perez-Pomares
José Luis De La PompaJosé Luis De La Pompa
José Luis De La Pompa
Epithelial-to-mesenchymal transition (EMT) is fundamental to both embryogenesis and tumor metastasis. The Notch intercellular signaling pathway regulates cell fate determination throughout metazoan evolution, and overexpression of activating alleles is oncogenic in mammals. Here we demonstrate that Notch activity promotes EMT during both cardiac development and oncogenic transformation via transcriptional induction of the Snail repressor, a potent and evolutionarily conserved mediator of EMT in many tissues and tumor types. In the embryonic heart, Notch functions via lateral induction to promote a selective transforming growth factor-β (TGFβ)-mediated EMT that leads to cellularization of developing cardiac valvular primordia. Embryos that lack Notch signaling elements exhibit severely attenuated cardiac snail expression, abnormal maintenance of intercellular endocardial adhesion complexes, and abortive endocardial EMT in vivo and in vitro. Accordingly, transient ectopic expression of activated Notch1 (N1IC) in zebrafish embryos leads to hypercellular cardiac valves, whereas Notch inhibition prevents valve development. Overexpression of N1IC in immortalized endothelial cells in vitro induces EMT accompanied by oncogenic transformation, with corresponding induction of snail and repression of VE-cadherin expression. Notch is expressed in embryonic regions where EMT occurs, suggesting an intimate and fundamental role for Notch, which may be reactivated during tumor metastasis.

9 November 2022 in Nature
Verified
Journal Article
Open access
PDF file
ACAdrià Cañellas-Socias
Adrià Cañellas-Socias
CCCarme Cortina
Carme Cortina
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
EMEoghan J. Mulholland
Eoghan J. Mulholland
EBEduard Batlle
Eduard Batlle
Around 30–40% of patients with colorectal cancer (CRC) undergoing curative resection of the primary tumour will develop metastases in the subsequent years1. Therapies to prevent disease relapse remain an unmet medical need. Here we uncover the identity and features of the residual tumour cells responsible for CRC relapse. An analysis of single-cell transcriptomes of samples from patients with CRC revealed that the majority of genes associated with a poor prognosis are expressed by a unique tumour cell population that we named high-relapse cells (HRCs). We established a human-like mouse model of microsatellite-stable CRC that undergoes metastatic relapse after surgical resection of the primary tumour. Residual HRCs occult in mouse livers after primary CRC surgery gave rise to multiple cell types over time, including LGR5+ stem-like tumour cells2,3,4, and caused overt metastatic disease. Using Emp1 (encoding epithelial membrane protein 1) as a marker gene for HRCs, we tracked and selectively eliminated this cell population. Genetic ablation of EMP1high cells prevented metastatic recurrence and mice remained disease-free after surgery. We also found that HRC-rich micrometastases were infiltrated with T cells, yet became progressively immune-excluded during outgrowth. Treatment with neoadjuvant immunotherapy eliminated residual metastatic cells and prevented mice from relapsing after surgery. Together, our findings reveal the cell-state dynamics of residual disease in CRC and anticipate that therapies targeting HRCs may help to avoid metastatic relapse.

30 September 2007 in Nature Genetics
Verified
Journal Article
Closed access
CCCarme Cortina
Carme Cortina
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
MIMar Iglesias
Mar Iglesias
JFJuan Luis Fernández-Masip
Juan Luis Fernández-Masip
AVAna Vivancos
Ana Vivancos
EBEduard Batlle
Eduard Batlle